Janux reports Q2 2026 results, keeps prostate cancer and autoimmune programs on track

Janux Therapeutics reported second quarter 2026 results on August 6, 2026, alongside an update on its clinical pipeline of immunotherapies.

JANX007, a PSMA-targeted TRACTr, continues to enroll in its Phase 1b trial in metastatic castration-resistant prostate cancer, with dose optimization and expansion ongoing in taxane-naive patients, including an expansion cohort combining JANX007 with the androgen receptor pathway inhibitor darolutamide.¹ JANX014, a double-masked tumor-activated T cell engager also targeting PSMA, continues enrollment in its Phase 1 study assessing safety, pharmacokinetics and preliminary antitumor activity.¹ JANX011, a CD19-targeted ARM, continues enrolling healthy volunteers in its Phase 1 trial.¹

On timelines, the company said initial clinical data from the Phase 1 healthy volunteer study of JANX011 is expected in the second half of 2026.¹ Clinical initiation of JANX013, a PSMA-targeted CD28 costimulatory TRACIr, is expected in the second half of 2026.¹ Additional clinical data for JANX007 is expected at a future medical congress in the first half of 2027.¹

On financials, Janux reported cash, cash equivalents and short-term investments of $970.9 million as of June 30, 2026, compared with $966.6 million on December 31, 2025.¹ Research and development expenses were $30,994 thousand (about $31.0 million) for the quarter, down from $34,664 thousand (about $34.7 million) a year earlier.¹ General and administrative expenses were $10,963 thousand (about $11.0 million), compared with $10,454 thousand (about $10.5 million) in the same period of 2025.¹ Net loss was $21,972 thousand (about $22.0 million) for the quarter, compared with a net loss of $33,858 thousand (about $33.9 million) in the prior-year period.¹